-
公开(公告)号：US10428077B2
公开(公告)日：2019-10-01
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10047103B2
公开(公告)日：2018-08-14
申请号：US15593534
申请日：2017-05-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US09688695B2
公开(公告)日：2017-06-27
申请号：US14396771
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
4.发明授权Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation 有权咪唑并噻二唑和咪唑并哒嗪衍生物作为治疗血小板聚集的蛋白酶活化受体4（PAR4）抑制剂公开(公告)号：US09518064B2
公开(公告)日：2016-12-13
申请号：US14396831
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Alain Martel , François Tremblay , Anne Marinier , Eldon Scott Priestley , Shoshana L. Posy , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , A61K38/12 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377
CPC classification number: C07D513/04 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K38/12 , C07D487/04
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US11407733B2
公开(公告)日：2022-08-09
申请号：US16311835
申请日：2017-06-28
Applicant: Universite de Montreal , Bristol-Myers Squibb Company
Inventor： Eldon Scott Priestley , Samuel Kaye Reznik , Edward H. Ruediger , James R. Gillard , Oz Scott Halpern , Wen Jiang , Jeremy Richter , Rejean Ruel , Sasmita Tripathy , Wu Yang , Xiaojun Zhang
IPC: C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D409/14 , C07D417/14 , C07D491/107 , C07D401/10 , C07D235/26 , C07D413/10 , C07D471/04 , C07D257/04 , C07D405/14 , C07D233/90 , C07D498/10 , C07D413/14 , A61P9/04 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/501 , C07D239/20 , C07D271/07
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
-
Patent Agency Ranking
公开(公告)号：US20180305376A1
公开(公告)日：2018-10-25
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/5377 , A61K31/435 , C07D487/04 , A61K31/541 , A61K31/553 , A61K31/433 , A61K31/496 , A61K31/497 , A61K31/454 , A61K45/06 , A61K31/4439 , A61K31/5025 , C07B59/00 , A61K31/55 , A61K51/04 , A61K31/5386 , C07D519/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
7.发明申请IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑并噻唑和咪唑并吡啶衍生物公开(公告)号：US20150094297A1
公开(公告)日：2015-04-02
申请号：US14396771
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Rèmillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/541 , A61K31/5377 , A61K31/5025 , C07D487/04 , A61K31/497 , A61K31/454 , A61K31/4439 , A61K31/433 , A61K31/553 , A61K31/496
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract translation: 本发明提供式I的噻唑化合物，其中W，Y，R0，R2，R4，R5，R6，R7，X1，X2，X3和X4如本文所定义，或立体异构体，互变异构体，药学上可接受的盐， 或其溶剂合物形式，其中所有变量如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。
-
公开(公告)号：US20240327390A1
公开(公告)日：2024-10-03
申请号：US18659052
申请日：2024-05-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Navnath Dnyanoba Yadav , Rajeev S. Bhide , Rajesh Onkardas Bora , Prashantha Gunaga , Manoranjan Panda , Eldon Scott Priestley , Jeremy Richter
IPC: C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04
CPC classification number: C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04
Abstract: Disclosed are compounds of Formula (I)
or a salt thereof,
wherein R1 is:
each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.-
公开(公告)号：US12037324B2
公开(公告)日：2024-07-16
申请号：US17861809
申请日：2022-07-11
Applicant: Université de Montréal , Bristol-Myers Squibb Company
Inventor： Eldon Scott Priestley , Samuel Kaye Reznik , Edward H. Ruediger , James R. Gillard , Oz Scott Halpern , Wen Jiang , Jeremy Richter , Rejean Ruel , Sasmita Tripathy , Wu Yang , Xiaojun Zhang
IPC: C07D401/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P9/04 , C07D233/90 , C07D235/26 , C07D239/20 , C07D257/04 , C07D271/07 , C07D401/10 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/10
CPC classification number: C07D401/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P9/04 , C07D233/90 , C07D235/26 , C07D239/20 , C07D257/04 , C07D271/07 , C07D401/10 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/10
Abstract: The present invention provides compounds of Formula (I):
wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.-
10.发明公开公开(公告)号：US20230242535A1
公开(公告)日：2023-08-03
申请号：US17902618
申请日：2022-09-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/454 , A61K31/5386 , A61K31/496 , A61K45/06 , C07B59/00 , A61K31/4439 , A61K31/5025 , A61K31/497 , A61K31/435 , A61K51/04 , A61K31/55 , C07D519/00 , A61K31/553 , A61K31/5377 , A61K31/433 , C07D513/04 , A61K31/541
CPC classification number: C07D487/04 , A61K31/55 , A61K31/433 , A61K31/435 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/541 , A61K31/553 , A61K31/4439 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K45/06 , A61K51/0453 , C07B59/002 , C07D513/04 , C07D519/00 , C07B2200/05
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.045 seconds)
